. Author manuscript; available in PMC: 2016 Nov 1.

Published in final edited form as: Nutr Metab Cardiovasc Dis. 2015 Jul 29;25(11):1016–1024. doi: 10.1016/j.numecd.2015.07.006

Table 3.

The association between energy-adjusted n3 polyunsaturated fat intake and CVD- and all-cause mortality

Model^*	Quintiles of n3 fatty acid intake					P for trend
Model^*	1 (reference)	2	3	4	5	P for trend
CVD mortality
Statin users	1.00	1.10 (0.82, 1.47)	0.94 (0.69, 1.27)	0.97 (0.72, 1.30)	0.90 (0.66, 1.23)	0.35
Non-users	1.00	0.93 (0.80, 1.09)	0.89 (0.76, 1.04)	0.85 (0.73, 1.01)	0.93 (0.78, 1.10)	0.57
All-cause mortality
Statin users	1.00	1.04 (0.87, 1.26)	1.13 (0.94, 1.36)	1.05 (0.87, 1.27)	1.06 (0.87, 1.28)	0.73
Non-users	1.00	0.99 (0.91, 1.07)	0.90 (0.83, 0.98)	0.91 (0.84, 1.00)	0.90 (0.82, 1.00)	0.04

Values are reported as hazard ratios (95% confidence intervals) and are computed from a model that included sex, race, BMI, recruitment site, education, income, smoking, alcohol consumption, total energy, energy-adjusted n3-PUFA, saturated fat, monounsaturated fat and proteins, diabetes, statin use and the interaction between n3-PUFA and statin use.